c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Se han encontrado 128 productos de "c-Met / HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Pamufetinib
CAS:<p>Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.</p>Fórmula:C27H23FN4O4SPureza:99.39%Forma y color:SolidPeso molecular:518.56Onartuzumab
CAS:<p>Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.</p>Pureza:97.3%Forma y color:LiquidPeso molecular:146.99 kDaJNJ-38877618
CAS:<p>JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).</p>Fórmula:C20H12F2N6Pureza:98.84% - 99.74%Forma y color:SolidPeso molecular:374.35Rilotumumab
CAS:<p>Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.</p>Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Forma y color:LiquidPeso molecular:145.2 kDaBozitinib
CAS:<p>Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.</p>Fórmula:C20H15F3N8Pureza:99.16%Forma y color:SolidPeso molecular:424.38c-Met inhibitor 1
CAS:<p>c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.</p>Fórmula:C17H14N8SPureza:98.77%Forma y color:SolidPeso molecular:362.41Emibetuzumab
CAS:<p>Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.</p>Pureza:SDS-PAGE:96.2%;SEC-HPLC:98.8%Forma y color:LiquidPeso molecular:143.74 kDaCSF1R-IN-2
CAS:<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>Fórmula:C20H20FN7O2Pureza:99.29%Forma y color:SolidPeso molecular:409.42Umikibart
<p>Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.</p>Forma y color:Odour LiquidPROTAC c-Met degrader-1
CAS:<p>PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.</p>Fórmula:C45H41FN10O5Forma y color:SolidPeso molecular:820.87c-Met-IN-23
<p>c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.</p>Fórmula:C16H13N7OPeso molecular:319.11816PF-04217903 phenolsulfonate
CAS:<p>PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).</p>Fórmula:C25H22N8O5SPureza:98%Forma y color:SolidPeso molecular:546.56Norleual
CAS:<p>Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.</p>Fórmula:C41H58N8O7Pureza:98%Forma y color:SolidPeso molecular:774.95LMTK3-IN-1
CAS:<p>Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.</p>Fórmula:C18H11F3N4OPureza:99.89%Forma y color:SoildPeso molecular:356.3BMS-777607
CAS:<p>BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.</p>Fórmula:C25H19ClF2N4O4Pureza:98.16% - 98.56%Forma y color:SolidPeso molecular:512.89Fosgonimeton acetate
<p>Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).</p>Fórmula:C29H49N4O10PPureza:98.01%Forma y color:SolidPeso molecular:644.69PROTAC c-Met degrader-3
<p>PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.</p>Fórmula:C51H54N10O7Forma y color:SolidPeso molecular:919.037SU 5616
CAS:<p>SU 5616 (WAY-608241) regulates abnormal cell proliferation and modulates tyrosine kinase signaling.</p>Fórmula:C13H8ClNOSPureza:98.84%Forma y color:SoildPeso molecular:261.73C-Met inhibitor D9
CAS:<p>C-Met inhibitor D9 is a c-Met kinase inhibitor.</p>Fórmula:C17H15N3O2Pureza:97%Forma y color:SolidPeso molecular:293.32Telisotuzumab
CAS:<p>Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.</p>Pureza:SDS-PAGE:96.4%;SEC-HPLC:98.5%Forma y color:LiquidPeso molecular:145.50 kDa
